ADAM-10 and -17 regulate endometriotic cell migration via concerted ligand and receptor shedding feedback on kinase signaling
- 14 May 2013
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences of the United States of America
- Vol. 110 (22), E2074-E2083
- https://doi.org/10.1073/pnas.1222387110
Abstract
A Disintegrin and Metalloproteinases (ADAMs) are the principal enzymes for shedding receptor tyrosine kinase (RTK) ectodomains and ligands from the cell surface. Multiple layers of activity regulation, feedback, and catalytic promiscuity impede our understanding of context-dependent ADAM “sheddase” function and our ability to predictably target that function in disease. This study uses combined measurement and computational modeling to examine how various growth factor environments influence sheddase activity and cell migration in the invasive disease of endometriosis. We find that ADAM-10 and -17 dynamically integrate numerous signaling pathways to direct cell motility. Data-driven modeling reveals that induced cell migration is a quantitative function of positive feedback through EGF ligand release and negative feedback through RTK shedding. Although sheddase inhibition prevents autocrine ligand shedding and resultant EGF receptor transactivation, it also leads to an accumulation of phosphorylated receptors (HER2, HER4, and MET) on the cell surface, which subsequently enhances Jnk/p38 signaling. Jnk/p38 inhibition reduces cell migration by blocking sheddase activity while additionally preventing the compensatory signaling from accumulated RTKs. In contrast, Mek inhibition reduces ADAM-10 and -17 activities but fails to inhibit compensatory signaling from accumulated RTKs, which actually enhances cell motility in some contexts. Thus, here we present a sheddase-based mechanism of rapidly acquired resistance to Mek inhibition through reduced RTK shedding that can be overcome with rationally directed combination inhibitor treatment. We investigate the clinical relevance of these findings using targeted proteomics of peritoneal fluid from endometriosis patients and find growth-factor–driven ADAM-10 activity and MET shedding are jointly dysregulated with disease.Keywords
This publication has 44 references indexed in Scilit:
- Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitorsNature, 2012
- Sequential Application of Anticancer Drugs Enhances Cell Death by Rewiring Apoptotic Signaling NetworksCell, 2012
- Dynamic Reprogramming of the Kinome in Response to Targeted MEK Inhibition in Triple-Negative Breast CancerCell, 2012
- Inhibition of PI3K/mTOR Leads to Adaptive Resistance in Matrix-Attached Cancer CellsCancer Cell, 2012
- Migration of growth factor-stimulated epithelial and endothelial cells depends on EGFR transactivation by ADAM17Nature Communications, 2011
- Shed HER2 extracellular domain in HER2‐mediated tumor growth and in trastuzumab susceptibilityJournal of Cellular Physiology, 2010
- Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLCCancer Cell, 2010
- Signal integration by JNK and p38 MAPK pathways in cancer developmentNature Reviews Cancer, 2009
- MMPs as therapeutic targets—Still a viable option?Seminars in Cell & Developmental Biology, 2008
- JNK phosphorylates paxillin and regulates cell migrationNature, 2003